Jaume Bosch

Summary

Country: Spain

Publications

  1. ncbi Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
    M D'AMICO
    Hepatic Hemodynamic Laboratory, Liver Unit and Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 302:G1191-8. 2012
  2. ncbi The clinical use of HVPG measurements in chronic liver disease
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic and CIBEREHD, University of Barcelona, Barcelona, Spain
    Nat Rev Gastroenterol Hepatol 6:573-82. 2009
  3. ncbi Vascular deterioration in cirrhosis: the big picture
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona and Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas Ciberehd, Barcelona, Spain
    J Clin Gastroenterol 41:S247-53. 2007
  4. ncbi Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver
    Jorge Gracia-Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic i Provincial, Barcelona, Spain
    Gut 60:517-24. 2011
  5. ncbi Variceal bleeding: pharmacological therapy
    Jaime Bosch
    Hepatic Hemodynamics Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Dig Dis 23:18-29. 2005
  6. ncbi Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension
    Jaume Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain
    J Hepatol 53:558-67. 2010
  7. ncbi Portal hypertension and gastrointestinal bleeding
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Semin Liver Dis 28:3-25. 2008
  8. ncbi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
  9. ncbi The management of portal hypertension: rational basis, available treatments and future options
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Hospital Clinic, C Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 48:S68-92. 2008
  10. ncbi Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability
    Jorge Gracia-Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metabòliques IMDiM, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    Hepatology 47:1248-56. 2008

Detail Information

Publications130 found, 100 shown here

  1. ncbi Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
    M D'AMICO
    Hepatic Hemodynamic Laboratory, Liver Unit and Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 302:G1191-8. 2012
    ....
  2. ncbi The clinical use of HVPG measurements in chronic liver disease
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic and CIBEREHD, University of Barcelona, Barcelona, Spain
    Nat Rev Gastroenterol Hepatol 6:573-82. 2009
    ..Responders have a markedly decreased risk of bleeding (or rebleeding), ascites, and spontaneous bacterial peritonitis, which results in improved survival...
  3. ncbi Vascular deterioration in cirrhosis: the big picture
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona and Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas Ciberehd, Barcelona, Spain
    J Clin Gastroenterol 41:S247-53. 2007
    ..Advances in the knowledge of the mechanisms of these abnormalities have disclosed new targets for therapy and ultimately improved survival...
  4. ncbi Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver
    Jorge Gracia-Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic i Provincial, Barcelona, Spain
    Gut 60:517-24. 2011
    ..This study aimed to assess whether abnormal intrahepatic haemodynamics in cirrhosis could modify KLF2 expression and consequently its downstream transcriptional programmes...
  5. ncbi Variceal bleeding: pharmacological therapy
    Jaime Bosch
    Hepatic Hemodynamics Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Dig Dis 23:18-29. 2005
    ....
  6. ncbi Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension
    Jaume Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain
    J Hepatol 53:558-67. 2010
    ....
  7. ncbi Portal hypertension and gastrointestinal bleeding
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Semin Liver Dis 28:3-25. 2008
    ..This article reviews the rationale for the management of portal hypertension and the current recommendations for the prevention and treatment of variceal bleeding...
  8. ncbi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
    ..Adverse events were comparable across groups...
  9. ncbi The management of portal hypertension: rational basis, available treatments and future options
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Hospital Clinic, C Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 48:S68-92. 2008
    ....
  10. ncbi Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability
    Jorge Gracia-Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metabòliques IMDiM, Hospital Clinic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    Hepatology 47:1248-56. 2008
    ..Conclusion: Our data show that oxidative stress may contribute to reduced NO bioavailability in cirrhotic livers, supporting the evaluation of O(2) (-) reduction as a potential mechanism to restore NO content...
  11. ncbi Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis
    Jorge Gracia Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, Ciberehd and Institut d Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Spain
    Gastroenterology 133:959-66. 2007
    ..Thus, our aims were to study the molecular and biochemical state of NADPH-oxidase in cirrhotic livers and to investigate its possible role in modulating hepatic vascular tone in cirrhosis...
  12. ncbi Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats
    Eugenio Rosado
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Ciberehd, University of Barcelona, Barcelona, Spain
    J Cell Mol Med 16:2461-70. 2012
    ..These strategies may have beneficial effects ameliorating the vasoconstrictor/vasodilator imbalance of the intrahepatic circulation of cirrhotic livers...
  13. ncbi Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis
    Aina Rodriguez-Vilarrupla
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malalties Digestives i Metabòliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, CIBERehd, Barcelona, Spain
    Liver Int 28:566-73. 2008
    ..The aim of this study was to evaluate the role of BK(Ca) channels in the regulation of vascular tone in control (CT) and carbon tetrachloride-cirrhotic (CH) rat livers...
  14. ncbi Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension
    Vincenzo La Mura
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Calle Villaroel 170, 08036 Barcelona, Spain
    J Hepatol 51:279-87. 2009
    ..However, two HVPG measurements are needed to evaluate response. This study was aimed at investigating the predictive role of acute HVPG response to i.v. propranolol for bleeding and survival...
  15. ncbi Insulin resistance in patients with cirrhosis and portal hypertension
    Eva Erice
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 302:G1458-65. 2012
    ..In nondiabetic patients with cirrhosis, HOMA-2 index is directly associated with the presence of CSPH and indirectly with varices, but does not allow either grading HVPG or predicting its response to propranolol...
  16. ncbi Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers
    Mariona Graupera
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 39:515-21. 2003
    ..The present study evaluates the role of cyclooxygenase (COX)-derived prostanoids, implicated in the pathogenesis of endothelial dysfunction in other settings, in the pathogenesis of endothelial dysfunction in cirrhotic livers...
  17. ncbi Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malaties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 37:1260-6. 2003
    ..However, the long-term use of this combination drug therapy is safe and may be an alternative in clinical conditions associated with a greater risk of bleeding...
  18. ncbi Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats
    Héctor García-Calderó
    Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    J Hepatol 54:660-5. 2011
    ..We aimed to evaluate whether a strategy directed to reduce superoxide using tempol, a small membrane permeable SOD-mimetic, is able to modulate intrahepatic nitric oxide content and reduce portal pressure in cirrhotic rats...
  19. ncbi Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers
    Mariona Graupera
    Hepatic Hemodynamic Laboratory, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 288:G763-70. 2005
    ..Despite abundant hepatic COX-2 expression, the increased response to Mtx of cirrhotic livers is mainly dependent of COX-1. Upregulation of COX-1 in cirrhotic SEC may be responsible for the hyperesponse to Mtx...
  20. ncbi A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis
    Javier Fernandez
    Liver Unit, IMDM and IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Hepatology 42:627-34. 2005
    ..This effect is due not only to volume expansion but also to an action on the peripheral arterial circulation...
  21. ncbi Angiogenesis in liver disease
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    J Hepatol 50:604-20. 2009
    ....
  22. ncbi PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
    Aina Rodriguez-Vilarrupla
    University of Barcelona, Spain
    J Hepatol 56:1033-9. 2012
    ..This study aims at evaluating the effects of PPARα activation with fenofibrate on hepatic and systemic hemodynamics, hepatic endothelial dysfunction, and hepatic fibrosis in CCl(4)-cirrhotic rats...
  23. ncbi Generation of 5 and 17 kDa human growth hormone fragments through limited proteolysis
    Gerard Such-Sanmartín
    Bio analysis group, Neuropsychopharmacology Program, Municipal Institute for Medical Research Hospital del Mar, Parque de Investigación Biomédica de Barcelona, Barcelona, Spain
    Growth Factors 27:255-64. 2009
    ..To evaluate this hypothesis, the activity of several endo-proteases on the 22 kDa hGH protein has been evaluated...
  24. ncbi Sonography of the caudate vein: value in diagnosing Budd-Chiari syndrome
    Xavier Bargallo
    Department of Radiology, Hospital Clinic, C Villarroel, 170, Barcelona 08036, Spain
    AJR Am J Roentgenol 181:1641-5. 2003
    ..The aim of this study was to evaluate the usefulness of sonography in measuring the caudate vein and lobe when diagnosing Budd-Chiari syndrome...
  25. ncbi Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis
    María Gabriela Delgado
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clínic Institut de Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Gastroenterol Hepatol 10:776-83. 2012
    ..We evaluated this therapy in a large series of patients with cirrhosis and non-neoplastic PVT...
  26. ncbi Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers
    Mariona Graupera
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malalties Digestives, University of Barcelona, Spain
    Hepatology 37:172-81. 2003
    ..SQ 29,548 also corrected the hyperresponse of cirrhotic livers to methoxamine. In conclusion, COX-derived prostanoids, mainly TXA(2), play a major role in regulating the response of cirrhotic livers to methoxamine...
  27. ncbi Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis
    Sebastian Raffa
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Clin Gastroenterol Hepatol 10:72-8. 2012
    ..We investigated the significance of these results...
  28. ncbi Acute and long-term effects of inhaled iloprost in portopulmonary hypertension
    Maria Teresa Melgosa
    Department of Pulmonary Medicine, University of Barcelona, Barcelona, Spain
    Liver Transpl 16:348-56. 2010
    ..Its long-term use may provide sustained improvements in symptoms and exercise tolerance in some patients with PoPH. A randomized, controlled trial is warranted to establish its clinical role in this serious condition...
  29. ncbi Growth hormone abuse and biological passport: is mannan-binding lectin a complementary candidate?
    Gerard Such-Sanmartín
    Bio Analysis Research Group, Neuropsychopharmacology Program, IMIM Hospital del Mar, PRBB, Barcelona, Spain
    Clin J Sport Med 21:441-3. 2011
    ..As a potential biomarker, mannan-binding lectin (MBL), which is reported to respond to recombinant GH (rGH) administration, is evaluated here...
  30. ncbi Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension
    Victoria Andreu
    Hepatic Hemodynamic Lab, Liver Unit, , , , University of Barcelona, Barcelona, Spain
    J Hepatol 44:1040-5. 2006
    ..The increased venous compliance is markedly attenuated by propranolol, suggesting that this abnormality is related to increased adrenergic activity...
  31. ncbi NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study
    Annalisa Berzigotti
    Hepatic Hemodynamics Laboratory, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 105:1094-101. 2010
    ..This study was aimed at testing the efficacy and tolerability of this compound in patients with cirrhosis and portal hypertension...
  32. ncbi TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial
    Angels Escorsell
    Hepatic Hemodynamic Laboratory, Liver Unit, , IDIBAPS, Barcelona, Spain
    Hepatology 35:385-92. 2002
    ..This suggests that TIPS should not be used as a first-line treatment, but as a rescue for failures of medical/endoscopic treatments (first-option therapies)...
  33. ncbi Total effective vascular compliance in patients with cirrhosis. Effects of propranolol
    Victoria Andreu
    Liver Unit, , Villarroel 170, 08036, Barcelona, Spain
    J Hepatol 36:356-61. 2002
    ..This abnormality is corrected by propranolol in patients exhibiting a >10% fall in HVPG, suggesting that changes in vascular compliance may influence the portal pressure response to propranolol...
  34. ncbi Prevention of variceal rebleeding
    Jaume Bosch
    Hepatic Haemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, 08036, Barcelona, Spain
    Lancet 361:952-4. 2003
    ..The role of HVPG monitoring as a guide to identifying patients requiring further treatment needs to be further evaluated. Trials to determine the best treatment for patients who do not respond to drug therapies are also required...
  35. ncbi Portal cholangiopathy: radiological classification and natural history
    Elba Llop
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona 08036, Spain
    Gut 60:853-60. 2011
    ..This study investigated the relationship between cholangiographic abnormalities and clinical symptoms and their evolution over time...
  36. ncbi Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, , Institut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Hepatology 37:902-8. 2003
    ....
  37. ncbi Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Centro de Investigación Biomèdica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 103:1159-67. 2008
    ..We aimed to develop a model based on noninvasive variables for the prediction of clinically significant portal hypertension (CSPH) and of esophageal varices (EV) in patients with compensated liver disease...
  38. ncbi Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy
    Beatriz Minguez
    Servei de Medicina Interna Hepatologia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Hepatology 43:707-14. 2006
    ..These disturbances, which include signs of increase in brain water and a compensatory osmotic response (decrease in brain myo-inositol), appear to be secondary to brain exposure to ammonia induced by portal-systemic shunting...
  39. ncbi Potential role of antioxidants in the treatment of portal hypertension
    Aina Rodriguez-Vilarrupla
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malalties Digestives i Metabòliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    J Hepatol 46:193-7. 2007
  40. ncbi Increasing intra-abdominal pressure increases pressure, volume, and wall tension in esophageal varices
    Angels Escorsell
    Hepatic Hemodynamics Laboratory, Liver Unit, IMD, , Barcelona, Spain
    Hepatology 36:936-40. 2002
    ..Increases in IAP may contribute to the progressive dilatation that precedes the rupture of the varices in portal hypertension...
  41. ncbi Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule
    Sandra March
    Immunology Unit, Department of Cellular Biology and Pathology, Medical School, University of Barcelona, Barcelona, Spain
    Am J Pathol 170:176-87. 2007
    ..Collectively, our data suggest that CD38 can act as a regulator of HSC activation and effector functions...
  42. ncbi Current concepts on the pathophysiology of portal hypertension
    Aina Rodriguez Vilarrupla
    Hepatic Hemodynamic Laboratory, Liver Unit Institut Malalties Digestives I Metabòliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, CIBER Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    Ann Hepatol 6:28-36. 2007
    ..This splanchnic arteriolar vasodilatation is a multifactorial phenomenon, which may involve neurogenic, humoral and local mechanisms...
  43. ncbi Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension
    Mar Coll
    Liver Diseases Laboratory, Liver Unit, Department of Internal Medicine, Institut de Recerca Hospital Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Liver Int 30:593-602. 2010
    ..We also attempted to localize the origin of mRNA of specific adrenergic genes...
  44. ncbi Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension
    Elsa Solá
    Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalunya, Spain
    Hepatology 52:1783-90. 2010
    ..It develops rapidly after start of therapy, may be severe in some patients and is associated with neurological complications, and is usually reversible after terlipressin withdrawal...
  45. ncbi Management of gastrointestinal bleeding in patients with cirrhosis of the liver
    Jaime Bosch
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Semin Hematol 41:8-12. 2004
    ..Specific sections on gastric varices and portal hypertensive gastropathy are included...
  46. ncbi Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 43:98-103. 2005
    ..To determine whether this process is angiogenesis-dependent, we assessed the effects of SU5416, a specific inhibitor of VEGF receptor-2, in portal hypertensive rats...
  47. ncbi Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera
    Alberto Alvarez-Larran
    Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Br J Haematol 124:329-35. 2004
    ..05). These results support a role for neutrophils in BCS/PVT secondary to PV and indicate that neutrophil CD11b expression could be of use for PV screening in BCS/PVT patients...
  48. ncbi Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension
    Susana Seijo
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Spain
    Dig Liver Dis 44:855-60. 2012
    ..This study evaluates specific findings at hepatic vein catheterisation or liver stiffness in idiopathic portal hypertension...
  49. ncbi Growth hormone secretagogues: out of competition
    Armand Pinyot
    Bioanalysis Group, Neurosciences Research Program, Municipal Institute for Medical Research Hospital del Mar, 08003 Barcelona, Spain
    Anal Bioanal Chem 402:1101-8. 2012
    ..5 h, and results were confirmed by comparison with a dedicated LC-MS quantification of the intact compound...
  50. ncbi Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Centre de Diagnòstic per l Imatge, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Liver Transpl 12:1791-8. 2006
    ..In conclusion, determination of liver stiffness is an extremely valuable tool to assess the severity of HCV recurrence after LT and in reducing the need of follow-up liver biopsies...
  51. ncbi Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis
    Javier Fernandez
    Liver Unit, IMD, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Hepatol 41:384-90. 2004
    ..Albumin administration prevents renal failure and improves survival in spontaneous bacterial peritonitis. This study characterizes the mechanisms of action of albumin in this condition...
  52. ncbi Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, CIBERehd, Universitat de Barcelona, Barcelona, Spain
    Hepatology 46:1208-17. 2007
    ..Importantly, these findings also suggest that an extended antiangiogenic strategy (that is, targeting VEGF/endothelium and PDGF/pericytes) may be a novel approach to the treatment of portal hypertension...
  53. ncbi Nitric oxide and portal hypertension
    Juan González-Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Metab Brain Dis 17:311-24. 2002
    ..Moreover, it cannot be ruled out that NO blockade may have a deleterious action on cirrhosis progression, which raises caution about their use in patients with cirrhosis...
  54. ncbi Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study
    Vincenzo La Mura
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Hepatology 51:2108-16. 2010
    ..CONCLUSION: The excellent prognostic information provided by HVPG response to drug therapy is lost if HAPG response is considered. RAP should not be used for the calculation of portal pressure gradient in patients with cirrhosis...
  55. ncbi Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension
    Mar Coll
    Liver Diseases Laboratory, Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d Hebron, Institut de Recerca Vall d Hebron, Universitat Autonoma de Barcelona, Pg Vall d Hebron 119 127, 08035 Barcelona, Spain
    J Hepatol 49:43-51. 2008
    ..Splanchnic vasodilation initiates the hyperdynamic syndrome in portal hypertension. We aimed to explore molecular mechanisms involved in the development of mesenteric vasodilation in portal hypertension...
  56. ncbi Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Gastroenterology 136:1651-8. 2009
    ..This randomized controlled trial evaluated the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG) and its safety in patients with cirrhosis and portal hypertension...
  57. ncbi Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis
    Pere Gines
    Liver Unit, Hospital Clinic, Institut d Investigacions Biomédiques August Pi Sunyer IDIBAPS, University of Barcelona, Instituto Reina Sofia de Investigacion Nefrologica, Barcelona, Catalunya, Spain
    Gastroenterology 123:1839-47. 2002
    ..However, its effect on survival and healthcare costs is still uncertain...
  58. ncbi Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis
    Juan Turnes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, , IDIBAPS, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Am J Gastroenterol 101:506-12. 2006
    ..Reduction of HVPG also correlate with a reduced risk of SBP or bacteremia...
  59. ncbi Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation
    Alejandro Blasco
    Liver Unit, Institut de Malalties Digestives, , , Barcelona, Spain
    Hepatology 43:492-9. 2006
    ..80), an HVPG of 6 mm Hg or greater was extremely accurate at identifying patients at risk of disease progression (AUC: 0.96). In conclusion, HVPG determination is a valuable tool for follow-up in patients with HCV recurrence after LT...
  60. ncbi Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension
    Manuel Hernandez-Guerra
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigaciones Biomèdiques August Pi i Sunyer, Barcelona, Spain
    Hepatology 43:485-91. 2006
    ..These results encourage the performance of further studies testing antioxidants as adjunctive therapy in the treatment of portal hypertension...
  61. ncbi Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats
    Maeva Guillaume
    Hepatic Haemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Ciberehd, University of Barcelona, Spain
    J Hepatol 58:240-6. 2013
    ....
  62. ncbi Left ventricular hypertrophy in rats with biliary cirrhosis
    Javier Inserte
    , Hospital Universitari Vall d'Hebron, Barcelona, Spain
    Hepatology 38:589-98. 2003
    ..This observation could be relevant to patients with cirrhosis...
  63. ncbi TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit Hospital Clínic, IDIBAPS and Ciberehd, Barcelona, Spain
    Gastroenterology 135:808-15. 2008
    ..However, the influence of TIPS on patient survival and factors that predict the outcome of TIPS in BCS patients remain unknown...
  64. ncbi Growth hormone in sport: beyond Beijing 2008
    Jordi Segura
    Bioanalysis and Analytical Services Research Group, Institut Municipal d Investigació Mèdica IMIM Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
    Ther Drug Monit 31:3-13. 2009
    ..In parallel with the new types of abuse, which will surely emerge in the near future, the research and development for the improvement of the analytical detection of GH itself will continue...
  65. ncbi Extrahepatic portal vein thrombosis
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Semin Liver Dis 28:282-92. 2008
    ..Mortality among patients with PVT is low (5-year mortality rate of 5 to 10%) and is mainly related to associated diseases rather than to complications of portal hypertension...
  66. ncbi The management of portal hypertension
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, ICMDM, Hospital Clinic, IDIBAPS, University of Barcelona, Villaroel 170 08036, Barcelona, Spain
    Clin Liver Dis 9:685-713, vii. 2005
    ..This article highlights treatment modalities in use for managing portal hypertension and those that may be available in the future...
  67. ncbi The treatment of acute variceal bleeding
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malalties Digestives i Metabòliques, Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Clin Gastroenterol 41:S312-7. 2007
    ..This paper reviews the most recent advancements in the general management and hemostatic treatments of acute variceal bleeding...
  68. ncbi Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial
    Jaime Bosch
    Hospital Clinic, Liver Unit, Barcelona, Spain
    Gastroenterology 127:1123-30. 2004
    ..This trial aimed to determine efficacy and safety of rFVIIa in cirrhotic patients with variceal and nonvariceal UGIB...
  69. ncbi Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain
    J Hepatol 48:229-36. 2008
    ....
  70. ncbi Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis
    Rafael Bañares
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain
    Hepatology 36:1367-73. 2002
    ..However, its clinical applicability may be limited by its systemic hypotensive effects. Further trials are needed to confirm the therapeutic potential of carvedilol...
  71. ncbi Medical management of variceal bleeding in patients with cirrhosis
    Juan G Abraldes
    Hospital Clinic, , University of Barcelona, Barcelona, Spain
    Can J Gastroenterol 18:109-13. 2004
    ..Administration of recombinant activated factor VII may decrease the number of treatment failures among patients with advanced liver failure (Child-Pugh class B and C)...
  72. ncbi Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis
    Carmen Zafra
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malaties Digestives, Hospital Clinic, Institut d'Investigacions Biomedique August Pi i Sunyer, University of Barcelona, Spain
    Gastroenterology 126:749-55. 2004
    ..CONCLUSIONS: Simvastatin administration increases the hepatosplanchnic output of nitric oxide products and decreases hepatic resistance in patients with cirrhosis...
  73. ncbi Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
    Marc Mejias
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, CIBERehd, Barcelona, Spain
    Hepatology 49:1245-56. 2009
    ....
  74. ncbi Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis?
    Jaime Bosch
    Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Nat Clin Pract Gastroenterol Hepatol 2:18-9. 2005
  75. ncbi Endoscopic band ligation in the treatment of portal hypertension
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Nat Clin Pract Gastroenterol Hepatol 2:526-35. 2005
    ..EBL, in combination with vasoactive drugs, is the recommended form of therapy for acute esophageal variceal bleeding; however, endoscopic injection sclerotherapy can be used in the acute setting if EBL is technically difficult...
  76. ncbi NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats
    Bernhard Angermayr
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions, Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Gut 56:560-4. 2007
    ..Therefore, it could be possible that activated NAD(P)H oxidases modulate angiogenesis in portal hypertension...
  77. ncbi Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Ciberehd and IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 132:1746-56. 2007
    ..Recurrence of hepatitis C virus (HCV) infection is a relevant problem of liver transplantation programs. We evaluated the effect of antiviral therapy on disease progression in 81 HCV-infected liver transplantation recipients...
  78. ncbi Early use of TIPS in patients with cirrhosis and variceal bleeding
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain
    N Engl J Med 362:2370-9. 2010
    ..This study evaluated the earlier use of TIPS in such patients...
  79. ncbi Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity
    Jordi Colmenero
    Liver Unit, Institut Clinic de Malalties Digestives i Metaboliques, Barcelona, Catalonia, Spain
    Gastroenterology 132:687-97. 2007
    ..Alcoholic hepatitis (AH) is a form of acute-on-chronic liver failure for which current therapy is not fully effective. We investigated the hepatic expression of candidate genes in patients with AH to identify new targets for therapy...
  80. ncbi Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model
    Raul Tonda
    Servicio de Hemoterapia Hemostasia, Hospital Clinic, Facultad de Medicina, IDIBAPS, Calle Villarroel 170, Barcelona 08036, Spain
    J Hepatol 39:954-9. 2003
    ..The exact mechanism of action of rFVIIa in this clinical condition is unknown. We have explored effects of rFVIIa on hemostasis in cirrhotic patients using an in vitro perfusion technique...
  81. ncbi Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome
    Graciela Martinez-Palli
    Servei d'Anestesiologia i Reanimacio Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    World J Gastroenterol 11:6858-62. 2005
    ..This data does not support the use of TIPS as a specific treatment for HPS. However, it does reinforce the view that TIPS can be safely performed for the treatment of other complications of portal hypertension in patients with HPS...
  82. ncbi Measurement of portal pressure and its role in the management of chronic liver disease
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, , IDIBAPS, University of Barcelona, Spain
    Semin Liver Dis 26:348-62. 2006
    ..Emerging, noninvasive methodologies for the evaluation of the patient with portal hypertension are also discussed...
  83. ncbi Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension
    Manuel Hernandez-Guerra
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    J Clin Gastroenterol 39:S131-7. 2005
    ..Some of these pharmacologic approaches have already been incorporated into clinical practice while others are still under investigation...
  84. ncbi Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy
    Pik Eu Chang
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Am J Gastroenterol 104:1707-14. 2009
    ..We describe for the first time the hepatic and systemic hemodynamic profile, liver stiffness, and histological features of eight patients with HIV-related IPH...
  85. ncbi [Vasoactive drugs for the treatment of bleeding esophageal varices]
    Jaime Bosch
    Liver Unit, IMD, Hospital Clinic et IDIBAPS, , Casanova, 143, 08036 Barcelone
    Gastroenterol Clin Biol 28:B186-9. 2004
  86. ncbi Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats
    Josephine Morales
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Hepatology 38:1378-83. 2003
    ..05). In conclusion, in hypovolemic portal-hypertensive rats during a portal hypertension-related bleeding, F-180 rapidly recovers arterial pressure and decreases transfusion requirements, blood losses, and mortality...
  87. ncbi Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation
    Juan Turnes
    Hepatic Hemodynamic Laboratory, Institut Malalties Digestives i Metabòliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Clin Gastroenterol Hepatol 6:1412-7. 2008
    ..Acute portal vein thrombosis (APVT) is a rare disorder that causes chronic portal hypertension if recanalization is not obtained. However, response to anticoagulation and long-term prognosis of APVT are not well-defined...
  88. ncbi Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats
    Vasilica Matei
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 49:192-7. 2008
    ..The main aim of the study was to evaluate the effect of tetrahydrobiopterin supplementation in portal pressure in CCl4 cirrhotic rats...
  89. ncbi P-selectin mediates leukocyte rolling in concanavalin-A-induced hepatitis
    Sandra March
    Immunology Unit, Department of Cellular Biology and Pathology, Medical School, University of Barcelona, Villaroel 170, Barcelona, Spain
    Liver Int 25:1053-60. 2005
    ..CONCLUSION: The results of this intravital microscopy study clearly demonstrate that P-selectin is involved in the initial leukocyte rolling that leads to the development of Con-A-induced liver injury...
  90. ncbi Characterisation of the 5 kDa growth hormone isoform
    Gerard Such-Sanmartín
    Pharmacology Research Unit, Municipal Institute for Medical Research IMIM, Barcelona, Spain
    Growth Factors 26:152-62. 2008
    ..This isoform can be easily obtained by solid phase synthesis methods. Our objective in this study is to describe this procedure in detail and to provide structural information of the protein...
  91. ncbi Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension
    Carolina Tiani
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, CIBERehd, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 50:296-305. 2009
    ..The apelin/APJ signaling pathway plays a crucial role in angiogenesis. Therefore, we determined whether the apelin system modulates angiogenesis-driven processes in portal hypertension...
  92. ncbi Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats
    Bernhard Angermayr
    Liver Unit, Hepatic Hemodynamic Laboratory, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 44:1033-9. 2006
    ..In this study, we determined the role of heme oxygenase-1 on oxidative stress, inflammation, angiogenesis, and splanchnic hemodynamics in rats with portal hypertension induced by partial portal vein ligation...
  93. ncbi The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis
    Vasilica Matei
    Hepatic Hemodynamic Laboratory, Liver Unit, , , , University of Barcelona, Barcelona, Spain
    Hepatology 44:44-52. 2006
    ..Tetrahydrobiopterin supplementation improved the endothelial dysfunction of cirrhotic livers...
  94. ncbi Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Insitut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Universityof Barcelona, Spain
    Gastroenterology 126:886-94. 2004
    ..The high relevance of these collateral vessels prompted us to investigate the mechanism underlying its formation in a murine model of portal hypertension...
  95. ncbi Utility of color Doppler ultrasonography predicting tips dysfunction
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, University of Barcelona, Spain
    Am J Gastroenterol 100:2696-701. 2005
    ..TIPS catheterization can be safely avoided in half of the patients using this predictive rule...
  96. ncbi 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes
    Mariona Graupera
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malaties Digestives Hospital Clinic, University of Barcelona, Barcelona, Spain
    Gastroenterology 122:387-93. 2002
    ..The aim of this study was to investigate the role of 5-lipoxygenase-derived eicosanoids regulating intrahepatic vascular tone in control and CCl4-induced cirrhotic rat livers...
  97. ncbi A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients
    Puneeta Tandon
    Hospital Clinic, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 105:1917-21. 2010
    ..We aimed to evaluate the dosing and tolerance of BBs achievable in a specialized, nurse-run BB titration clinic with non-trial participants...
  98. ncbi Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, CIBERehd, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 46:1040-6. 2007
    ..Statins improve endothelial dysfunction in peripheral vasculature. This study was designed to characterize the hemodynamic and molecular effects of statins in cirrhotic rats...
  99. ncbi Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis
    Lia Bellis
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, Barcelona, Spain
    Hepatology 37:378-84. 2003
    ..The same was observed in patients receiving propranolol. Our results suggest that therapeutic strategies based on selective hepatic NO delivery may improve the treatment of portal hypertension...
  100. ncbi Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers
    Jorge Gracia-Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, Ciberehd and Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 47:220-7. 2007
    ..Our study was aimed at investigating the role of enhanced AA bioavailability modulating the hepatic vascular tone of cirrhotic livers and identifying which prostanoid is involved...
  101. ncbi Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis
    Marlene Dominguez
    Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Ciber de Enfermedades Hepaticas y Digestivas, Barcelona, Catalonia, Spain
    Gastroenterology 136:1639-50. 2009
    ..We performed a prospective study to associate hepatic expression of the CXC subfamily of chemokines with histology findings and prognosis of patients with AH...